EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer

Adisorn Ratanaphan iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26209881 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Adisorn Ratanaphan. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla 90112, Thailand. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, BRCA1 Protein, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science, Research and Innovation Fund (NSRF) and Prince of Songkla University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) accounts for about 10–15% of all breast cancers and is an aggressive disease with a poor prognosis. There is currently no standard treatment regimen for TNBC patients; thus, chemotherapy remains the main treatment. Anthracycline- and taxane-based regimens are the most widely used in a clinical setting, either alone or in combination with other chemotherapeutic agents, including poly (ADP-ribose) polymerase (PARP) inhibitors and platinum drugs. Platinum drugs have been used particularly in patients with BRCA1-mutated TNBC. Preclinical and clinical trials revealed that the response to PARP inhibition was directly correlated to the sensitivity to platinum chemotherapies. Inhibition of PARP enzymes has been shown to specifically target BRCA1 dysfunctional cells. Therefore, targeting breast cancer cells that possess genetic alterations that are absent in normal cells could be attained by the exploitation of synthetic lethality for the discovery of other candidate metals, i.e., ruthenium-derived compounds, as next-generation drugs for the treatment of TNBC. This prospective approach provides new insight into alternative treatments for breast cancers with BRCA1-associated TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinAntineoplastic AgentsHumansFemaleAnimals

Stichwörter der Autor:innen

BRCA1 dysfunctionPARP inhibitorsmetal-based drugssynthetic lethalitytriple-negative breast cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla 90112, Thailand.

ORCID-Profile: Adisorn Ratanaphan

Förderung

  • National Science, Research and Innovation Fund (NSRF) and Prince of Songkla University

Zitieren

APA

Ratanaphan, A. (2025). Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26209881

Vancouver

Ratanaphan A. Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26209881

BibTeX
@article{Ratanaphan2025,
  author = {Ratanaphan, Adisorn},
  title = {Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26209881}
}
Kostenlos starten →